Basildon (UK), 19 March 2020 – On 11 March 2020 the World Health Organization (WHO) declared a pandemic in response to the COVID-19 outbreak. This is a serious health situation and we extend our sympathies to patients and relatives and acknowledge the efforts of healthcare professionals.
Our primary concern is the health and safety of both our patients and our staff across the world. This means we must endeavour to maintain supply, and at the same time, we must not put our staff at risk.
We are currently fully operational and do not anticipate any disruption to either our distribution network or supply chain at this stage. We have not yet identified any material continuity risks specifically associated with COVID-19, and we continue to monitor the situation carefully.
We have requested all our staff across our offices in Basildon, Copenhagen and Vadodara to work from home from 23 March 2020. We employ a suite of digital tools to support internal collaboration and external communication, and we can access all our systems remotely. If you have any queries, please contact us via the usual channels or email@example.com.
We thank you for your understanding during this challenging time and we wish you, your friends, your colleagues and your families safe health.
Atnahs is a specialty pharmaceutical business, focused on acquiring mature branded medicines out of large cap and specialty pharma companies globally and developing its own niche medicines. Atnahs operates a portfolio of 21 brands with over 1,900 SKUs across more than 144 markets, with a focus on therapeutic areas such as Cardiovascular, Women’s Health & Endocrinology, Neurology & Pain, and Gastroenterology & Oncology.